Huntington's Disease Foundation

Huntington's Disease Foundation The mission of the Huntington's Disease Foundation is to fund transformative research to find treatments, and ultimately a cure, for Huntington's disease.

The mission of the Huntington's Disease Foundation is to fund transformative research to find treatments, and ultimately a cure, for Huntington’s disease and other related disorders.

Today is DAF Day! If you have a donor-advised fund, consider recommending a grant to the Huntington’s Disease Foundation...
10/08/2026

Today is DAF Day! If you have a donor-advised fund, consider recommending a grant to the Huntington’s Disease Foundation.

Your gift helps advance HD research, support early-career scientists, and bring researchers together to share discoveries—all working toward effective treatments and ultimately a cure.

Learn how to give through your DAF: https://bit.ly/DAFInfo

Celebrate the power of giving by spreading the word. Thank you for supporting research and hope for families affected by Huntington’s disease.

uniQure issued a press release today announcing additional data from the ongoing Phase I/II clinical studies of ifezunti...
09/29/2026

uniQure issued a press release today announcing additional data from the ongoing Phase I/II clinical studies of ifezuntirgene inilparvovec (AMT-130), uniQure's investigational gene therapy for Huntington's disease.

uniQure stated the key points announced in today’s press release include:

→The data announced included analyses at two timepoints

→In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008)

→Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anchor for the submitted BLA and the confirmatory study; the new analysis demonstrated 80% slowing of disease progression based on cUHDRS (nominal p=0.005) and 67% based on TFC (nominal p=0.011)

→Treatment effect at 48 months likely understated by substantial missing data and survivor bias in updated external control; post hoc analysis using prior external control showed slowing of disease of 54% on cUHDRS (nominal p=0.041)and 68% on TFC (nominal p=0.001) at 48 months

→These positive data are meaningful for Huntington's disease patients who currently have no approved disease-modifying treatment options.

Read more: bit.ly/HDF-PR

Letters of Intent are due by THIS THURSDAY!The Huntington's Disease Foundation is currently accepting Letters of Intent ...
09/28/2026

Letters of Intent are due by THIS THURSDAY!

The Huntington's Disease Foundation is currently accepting Letters of Intent for Postdoctoral Fellowships and Grants. We invite you to look at the Apply page on our website to learn more and submit your application. Letters of Intent are due by October 1, 2026.

https://hdfoundation.org/apply/

Letters of Intent are due NEXT WEEK!The Huntington's Disease Foundation is currently accepting Letters of Intent for Pos...
09/24/2026

Letters of Intent are due NEXT WEEK!

The Huntington's Disease Foundation is currently accepting Letters of Intent for Postdoctoral Fellowships and Grants. We invite you to look at the Apply page on our website to learn more and submit your application. Letters of Intent are due by October 1, 2026.

https://hdfoundation.org/apply/

The Huntington's Disease Foundation is currently accepting Letters of Intent for Postdoctoral Fellowships and Grants. We...
09/17/2026

The Huntington's Disease Foundation is currently accepting Letters of Intent for Postdoctoral Fellowships and Grants. We invite you to look at the Apply page on our website to learn more and submit your application. Letters of Intent are due by October 1, 2026.

https://hdfoundation.org/apply/

WATCH NOW! Drs. Rachel Harding and Leora Fox from HDBuzz joined us last week to share the buzz from HDF’s recent HD2026...
09/17/2026

WATCH NOW! Drs. Rachel Harding and Leora Fox from HDBuzz joined us last week to share the buzz from HDF’s recent HD2026: 14th Milton Wexler Biennial Symposium. They gave a brief but thorough overview about some of the exciting science from the meeting and answered many of your questions.

Watch the webinar now: https://www.youtube.com/watch?v=OmvcoQ6pOvk

JOIN US TODAY AT 12NOON ET as Drs. Rachel Harding and Leora Fox from HDBuzz share the buzz from HDF’s recent HD2026: 14...
09/09/2026

JOIN US TODAY AT 12NOON ET as Drs. Rachel Harding and Leora Fox from HDBuzz share the buzz from HDF’s recent HD2026: 14th Milton Wexler Biennial Symposium. They will recap some of the exciting science from the meeting and hold a live Q&A. Join us and get your questions about Huntington’s disease research ready!

Register Now: https://us06web.zoom.us/webinar/register/5017861600267/WN_xs2fDlHmR3eKXbMesQAPyQ

HD2026 Symposium Recap with HDBuzz
Wednesday, September 9, 2026
12-1pm ET

Rachel J. Harding, PhD
University of Toronto
Structural Genomics Consortium
Princess Margaret Cancer Centre, UHN
2024 Nancy S. Wexler Young Investigator Prize recipient
2026 Transformative Research Award recipient

Leora Fox, PhD
Fox Scientific Consulting, LLC

TUNE IN TOMORROW! Rachel and Leora from HDBuzz will join us to share updates from HDF’s HD2026 biennial conference. The...
09/08/2026

TUNE IN TOMORROW! Rachel and Leora from HDBuzz will join us to share updates from HDF’s HD2026 biennial conference. They’ll also be available for a live Q&A – ask them anything!

Register Now: https://us06web.zoom.us/webinar/register/5017861600267/WN_xs2fDlHmR3eKXbMesQAPyQ

HD2026 Symposium Recap with HDBuzz
Wednesday, September 9, 2026
12-1pm ET

Rachel J. Harding, PhD
University of Toronto
Structural Genomics Consortium
Princess Margaret Cancer Centre, UHN
2024 Nancy S. Wexler Young Investigator Prize recipient
2026 Transformative Research Award recipient

Leora Fox, PhD
Fox Scientific Consulting, LLC

At HDF's HD2026 Symposium, a record crowd of some 300 researchers from around the globe pushed the frontiers of science ...
09/03/2026

At HDF's HD2026 Symposium, a record crowd of some 300 researchers from around the globe pushed the frontiers of science in their urgent quest for treatments for Huntington's disease, a devastating, deadly brain disorder.

From genome editing to artificial intelligence (AI) as a research tool, from HD as a developmental advantage to clinical trial programs, HD2026 explored the hottest topics in Huntington’s science. The symposium took place in the spirit of the HDF’s emphasis on collaboration and group brainstorming, including a two-day genome-editing workshop beforehand for specialists. Participants included academics, biopharma reps, advocates like me, and leaders of other HD organizations.

Click here to read the overview of HD2026 and key highlights: https://hdfoundation.org/hd2026-recap-summary/

Address

601 West 168th Street, Suite 54
New York, NY
10032

Telephone

(212) 928-2121

Website

Alerts

Be the first to know and let us send you an email when Huntington's Disease Foundation posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Huntington's Disease Foundation:

Shortcuts

Featured

Share

Category